Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Rerouting mRNA for in vivo chimeric antigen receptor immune cell therapy

Project description

Nanoparticles for in vivo cell immunotherapy

Immunotherapy based on T cells expressing chimeric antigen receptors (CARs) has transformed cancer treatment, but it remains expensive, complex and largely limited to haematologic malignancies. Developing methods that produce therapeutic immune cells directly inside the body could make this treatment far more accessible. Nanoparticles offer a promising vehicle for delivering the genetic instructions needed to achieve this. The ERC-funded REROUTING CAR project aims to develop apolipoprotein nanoparticles to deliver mRNA encoding cancer-targeting receptors directly to immune cells in vivo. Researchers will follow a multidisciplinary approach to screen nanoparticle formulations for effective mRNA delivery to specific immune cells. Successful completion will yield a versatile nanomedicine platform for in vivo CAR immune cell therapy. Potential applications extend to autoimmune and cardiovascular diseases.

Objective

Chimeric antigen receptor (CAR) T cell therapy has revolutionized cancer treatment. Nevertheless, CAR T cell therapy is clinically limited to hematological malignancies and hampered by its complex and costly ex vivo manufacturing procedure. To render this treatment cost-effective and available for diverse cancer types, in vivo CAR immune cell therapy strategies must be developed.
My group has established new apolipoprotein nanoparticle (aNP) platform technology for RNA delivery to immune cells. Leveraging lipoproteins’ natural delivery features, our technology combines tunable biodistribution features with a superb biocompatibility profile. Building on this concept, I propose developing aNPs containing messenger RNA (mRNA) encoding CARs to be delivered and expressed by specific immune cells.
Based on compelling preliminary data, I will pursue two Key Objectives:
KO1: Using advanced microfluidic production methods, we will establish a library of self-assembling aNPs – composed of natural phospho(lipids), ionizable cationic materials and apolipoprotein A1 (apoA1), and containing mRNA – and screen barcoded aNPs’ ability to functionally deliver mRNA to immune cells in vivo. Machine learning analysis will provide lead formulations for in vivo CAR monocyte/macrophage (CAR M) proof-of-concept therapeutic studies in a solid tumor mouse model.
KO2: Using proprietary apoA1-nanobody fusion protein technology, we will screen targeted mRNA-aNPs’ ability to induce functional gene expression in specific immune cells in vivo. Lead aNP-mRNA formulations will be used for in vivo CAR T proof-of-concept therapeutic studies in a hematological mouse tumor model.
This Program’s successful completion will yield a unique, versatile nanomedicine approach that can be employed to induce in vivo CAR immune cell therapy for cancer treatment, with significant translational potential and pertinency for applications in non-malignant diseases such as autoimmune disorders and cardiovascular disease.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-COG

See all projects funded under this call

Host institution

TECHNISCHE UNIVERSITEIT EINDHOVEN
Net EU contribution
€ 2 000 000,00
Address
GROENE LOPER 3
5612 AE Eindhoven
Netherlands
Region
Zuid-Nederland Noord-Brabant Zuidoost-Noord-Brabant
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 2 000 000,00

Beneficiaries (1)